Tesamorelin: the one GHRH drug with phase 3 evidence, and what it does and doesn’t show

Tesamorelin is the only growth hormone-releasing peptide in this family with proper phase 3 evidence and a current FDA approval. In people with HIV and excess abdominal fat, daily injections cut visceral fat by around 15% relative to placebo over six months [1,3]. That result is solid. It is also narrow: the fat returned when treatment stopped [2], the drug was never approved in Europe [9], and the uses it is often promoted for, from general fat loss to anti-ageing, have not been tested in trials.

What it is

Tesamorelin is the full 44-amino-acid human growth hormone-releasing hormone, GHRH(1-44), with a six-carbon hexenoyl chain attached to its first amino acid [7]. Researchers describe it as a stabilised analogue of human GHRH [6]. Like sermorelin and CJC-1295, it acts on the GHRH receptor in the pituitary and makes the gland release more of its own growth hormone, which in turn raises IGF-1 [7].

The clinical idea behind it came from HIV medicine. Some people on antiretroviral therapy build up visceral fat, the deep fat packed around the abdominal organs, which is linked to higher cardiovascular risk [1]. Tesamorelin was tested as a way to shrink that fat by raising the patient’s own growth hormone, rather than by injecting growth hormone itself [1].

It is sold in the US as Egrifta. The original product was approved in November 2010 [8]; the current formulation, Egrifta WR, is more concentrated and is mixed once a week rather than daily, although it is still injected every day [7].

The human evidence

The phase 3 programme

Two large randomised, placebo-controlled trials underpin the approval. Both enrolled adults with HIV on antiretroviral therapy with excess abdominal fat, measured visceral fat by CT scan, and gave 2 mg of tesamorelin or placebo under the skin daily for 26 weeks, followed by a 26-week extension.

In the first trial, visceral fat fell by 15.2% on tesamorelin and rose by 5.0% on placebo [1]. Triglycerides and the cholesterol-to-HDL ratio also improved. IGF-1 rose by 81%. Adverse events did not differ significantly overall, though more people on tesamorelin dropped out because of one [1].

The second trial, in 404 patients, found a smaller effect: visceral fat fell 10.9% (21 cm²) against 0.6% on placebo at six months, and by about 18% in those who stayed on the drug for a full year [2]. Trunk fat and waist size improved; fat under the skin and in the limbs did not change. The key extension finding was about stopping. In people switched from tesamorelin to placebo after six months, the authors reported that the visceral fat improvements were “rapidly lost” [2]. The prescribing information gives the numbers from the first trial’s extension: over the next 26 weeks, visceral fat rose by an average 25 cm² (22%) in those moved to placebo, against 3 cm² in those who stayed on the drug [7]. In practical terms, tesamorelin works for as long as it is injected every day.

Pooling both trials, 806 patients were randomised 2:1. The treatment effect on visceral fat at 26 weeks was −15.4% relative to placebo, with no significant change in fat just under the belly skin [3]. People also rated their belly appearance as less distressing [3].

Two things are worth being clear about. First, this is a change in one fat depot on a CT scan. Tesamorelin is described in its label as weight neutral and is explicitly “not indicated for weight loss management” [7]. Second, no trial has shown fewer heart attacks, strokes or deaths; the label states that long-term cardiovascular safety has not been established [7].

Liver fat

A smaller trial at Massachusetts General Hospital randomised 50 people with HIV and abdominal fat to tesamorelin or placebo for six months [4]. Visceral fat fell by a net 42 cm², and liver fat fell modestly, a net 2.9 percentage points in lipid-to-water ratio. Fasting glucose rose at two weeks but was not significantly different by six months [4].

The same group then tested tesamorelin specifically in fatty liver disease. In 61 people with HIV and at least 5% liver fat, a year of tesamorelin reduced liver fat by an absolute 4.1 percentage points more than placebo, a 37% relative reduction [5]. At 12 months, 35% on tesamorelin versus 4% on placebo had liver fat below 5% [5]. Glucose and HbA1c did not differ between groups. The authors were careful to say longer studies are needed to know whether this changes liver damage over time [5].

Cognition in older adults

Outside HIV, the most notable trial randomised 152 adults aged 55 to 87, 66 of them with mild cognitive impairment, to 1 mg of tesamorelin or placebo nightly for 20 weeks [6]. The combined cognitive score favoured tesamorelin (p = 0.03), driven mainly by executive function; verbal memory showed only a trend. Body fat fell 7.4%. Adverse events, mostly mild, were reported by 68% on tesamorelin and 36% on placebo [6]. It is a single, modest trial with composite outcomes and has not led to an approved use.

Outside HIV: what the evidence does not cover

Tesamorelin now circulates well beyond HIV clinics, promoted for general belly fat, body recomposition and healthy ageing. None of those uses has a completed trial behind it that we could find. The phase 3 participants were adults on antiretroviral therapy, mostly men, with a mean age of 48 [7]. The drug lowered a specific fat depot in that group without changing body weight. Whether the same happens in people whose visceral fat has other causes, and whether it would matter for their health, is unknown. The European regulator’s hesitation was partly about exactly this: in everyday practice, it is hard to separate lipodystrophy-related fat from ordinary obesity [9].

The cognitive trial is the only substantial non-HIV study, and it measured thinking tests, not body composition as a primary outcome [6].

Safety and side effects

Because tesamorelin went through a full approval process, its side-effect profile is better documented than any other peptide in this group. From the US prescribing information [7]:

• Injection-site reactions in 25% on tesamorelin versus 14% on placebo over 26 weeks.
• Joint pain, limb pain, muscle pain and swelling of the legs were more common than on placebo, consistent with growth hormone-driven fluid retention; carpal tunnel syndrome can occur.
• Blood sugar: 5% on tesamorelin versus 1% on placebo developed HbA1c in the diabetes range, a hazard ratio of 3.3. The label advises checking glucose before and during treatment.
• IGF-1: after 26 weeks, 47% had IGF-1 more than two standard deviations above normal and 36% more than three. The long-term effect of that is unknown, and the label advises monitoring.
• Antibodies: half of patients developed antibodies to tesamorelin by 26 weeks. About 60% of those cross-reacted with the body’s own GHRH, though fat and IGF-1 responses were similar with or without antibodies.
• Hypersensitivity reactions in 4%.

It is contraindicated in pregnancy, active cancer, and in people whose hypothalamic-pituitary axis has been disrupted, for example by pituitary surgery or tumour, hypopituitarism, head irradiation or head trauma [7].

Legal and regulatory status

• US: FDA-approved (Egrifta, first approved 10 November 2010) for reducing excess abdominal fat in adults with HIV and lipodystrophy [8]. The Egrifta WR formulation was approved in March 2025 [7].
• EU: never approved. Ferrer withdrew its marketing application in 2012 after the European Medicines Agency’s committee indicated it could not conclude that benefits outweighed risks, partly because excess fat from lipodystrophy is hard to tell apart from ordinary obesity in practice [9].
• UK: we found no UK licence.
• Sport: prohibited at all times; tesamorelin is named under S2.2.4 of the 2026 WADA Prohibited List [10].

What we still don’t know

• Whether reducing visceral fat with tesamorelin lowers cardiovascular events or extends life in people with HIV.
• Whether any benefit carries over to people without HIV who have excess visceral fat. The approval trials did not include them.
• What years of raised IGF-1 mean for cancer risk and glucose control.
• Whether the liver-fat improvement changes fibrosis or long-term liver outcomes.
• Whether the cognitive signal in older adults would survive a larger, longer trial.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR×Proper Protocols